Release date: 24 June 2009
Promoter – Financial Intermediary
ALK-Abello A/SLocation
Description
The project consists of Alk Abello's R&D activities, particularly those related to the development tablet based treatments for trees and ragweed pollen allergy, house dust mite and cat allergy and to the development of scientific models that lead to a better understanding of the immunological mechanisms of allergy and vaccination therapy, which can be used in next generation immuno-allergy vaccines. The project will be implemented in the period 2009-2010.
Objectives
The project should strengthen the market position of one of the EU-based market leaders, operating in the global market for allergen immunotherapy.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 40 million.
Total cost (Approximate amount)
EUR 97.5 million.
Environmental aspects
The project is expected to have no significant environmental impact.
Procurement
Procurement is in line with EIB guidelines for the private sector projects.
Status
Signed - 10/06/2010